Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
In patients with type 2 diabetes at high cardiovascular risk, empagliflozin was associated with slower progression of kidney disease and lower rates of clinically relevant renal...
Publications
3 shownRenal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
Background— The primary objective of this mechanistic open-label, stratified clinical trial was to determine the effect of 8 weeks’ sodium glucose cotransporter 2 inhibition wit...
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
ClinicalTrials.gov Identifier: NCT01897532.
Frequent Co-Authors
Researcher Info
- h-index
- 3
- Publications
- 3
- Citations
- 5,743
- Institution
- Boehringer Ingelheim (Taiwan)
External Links
Impact Metrics
h-index
3
h-index: Number of publications with at least h citations each.